CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.

Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the ...

The recent approvals of Leqembi (lecanemab) and Kisunla (donanemab) have refreshed the landscape of Alzheimer’s disease treatments. For the first time, patients have the option to take a drug that ...

While you'd be forgiven for confusing the upcoming "A Quiet Place Part III" with the franchise's third entry, the prequel "A Quiet Place: Day One," a proper follow-up continuing the Abbott family ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

A tree nut allergy occurs when a person cannot eat a certain type of nut because their immune system deems certain proteins found within it as harmful. This causes a reaction that can come with mild ...

What’s inside this Plumpy’Nut® sachet that has saved millions of children? Plumpy’Nut®, also known as ready-to-use therapeutic food (RUTF), is a high-energy peanut paste containing sugar, vegetable ...